

Clinical impact of bone and calcium metabolism changes in sarcoidosis

Gianfranco Rizzato

History

BONE CHANGES

Even before the introduction of X-rays, Besnier¹ had noted the association of swelling of the fingers with lupus pernio. In 1904 Karl Kreibich, later Professor of Dermatology in Prague but at that time working in Vienna, described four patients with cystic changes in the bones of the hand in connection with lupus pernio and gave an excellent radiographic reproduction of the hands in one and sarcoid histology of the skin in another.² Other reports showing bone involvement by sarcoidosis were published soon thereafter.³⁻⁶ In 1919 Schaumann⁵ was the first to emphasise the location of the specific granuloma in the marrow. The first detailed accounts of the radiology were those of Fleiscner⁷ and Jungling⁸ who demonstrated that radiological involvement is more frequent in the bones of the hands and feet than in the long bones, vertebrae, or skull. James⁹ in 1959 was the first to recognise that bone involvement occurs very rarely in the absence of skin lesions but is common in patients with persistent disease, especially with lupus pernio and other skin lesions.¹⁰ The first study on trabecular osteoporosis in 49 untreated patients was possible only when computed tomography became available¹¹; our group has shown that a mild trabecular bone loss may appear only in chronic sarcoidosis. This feature had never been noted before because simple radiographic studies are not sensitive enough to show a mild osteoporosis and because there is rarely an indication for biopsy of the bone affected by sarcoidosis. Our findings have been confirmed by two other groups.¹²⁻¹⁵

Corticosteroids may, of course, cause osteoporosis¹⁴ which is spontaneously reversible, at least in young people, if the treatment can be discontinued for at least six months.¹⁵

CALCIUM METABOLISM CHANGES

Hypercalcaemia in sarcoidosis was first demonstrated in 1939.¹⁶ The next milestone was the discovery in 1979 that increased serum concentrations of 1,25-dihydroxy-vitamin D₃ (calcitriol; 1,25(OH)₂D₃) are associated with the hypercalcaemia in sarcoidosis.¹⁷⁻¹⁸ Two years later it became clear that the site for overproduction of calcitriol must be extrarenal since hypercalcaemia and raised calcitriol levels were observed in an anephric patient with sarcoidosis.¹⁹ The puzzle was finally solved in 1983 with the report that cultured alveolar macrophages in sarcoidosis are able to produce calcitriol.²⁰

Epidemiology

Bone involvement is reported to be from 1% to 34% depending on the primary interest of the author and whether a radiological evaluation of the bones has been performed,²¹ though the recognition of this problem has increased since the introduction of computed tomographic (CT) scanning. In an untreated group of patients we have found that, when sarcoidosis was known for at least 20 months, vertebral cancellous mineral content was lower than normal (>1 SD below normal—that is, Z score < -1) in seven of 14 men, in four of six young women, and in three of five postmenopausal women. Thus, over 50% of patients with chronic sarcoidosis had osteopenia.²²

Hypercalcaemia (above 11 mg/dl or above 0.11 kg/m³) occurs in less than 10% and clinically important hypercalcaemia probably occurs in less than 5% of patients with sarcoidosis.²³ Hypercalciuria is found more frequently. Taking an upper limit of urinary calcium excretion rate of 300 mg/24 hours, it was found in 77 (40%) of 192 patients in London.²⁴ Renal calculi have been found in about 10% of patients with chronic sarcoidosis, with a prevalence ranging from 1.3% to 14%.²⁵⁻³⁰ In rare cases (2.2% in one retrospective study, 3.6% in one prospective study) they may be the presenting feature of the disease.³¹⁻³² Moreover, there may be asymptomatic renal stones at presentation in a further 2.7%.³²

Pathogenesis of extrarenal synthesis of 1,25(OH)₂D₃: a compensatory mechanism mounted by the immune system?

The structure of the 1,25(OH)₂D₃ that was synthesised by the sarcoid alveolar macrophages was confirmed by mass spectroanalysis.³³ Production of 1,25(OH)₂D₃ in the system was enhanced in a dose dependent fashion by γ -interferon.³⁴⁻³⁵ γ -Interferon is produced spontaneously by activated lymphocytes and alveolar macrophages in active sarcoidosis.³⁶ These findings provide evidence that γ -interferon plays a major role in the pathogenesis of extrarenal synthesis of 1,25(OH)₂D₃.

Alveolar macrophages recovered by bronchoalveolar lavage from patients with sarcoidosis possess 1 α -hydroxylase activity and are able to metabolise 1,25(OH)₂D₃ from 25-hydroxy-vitamin D₃.²⁰ Substrate specificity and enzyme affinity for 25-hydroxy-vitamin D₃ are similar to those reported for the renal enzyme.³⁴ Whereas synthesis of 1,25(OH)₂D₃ by the pulmonary alveolar macrophages and mammalian kidney show some similarities, 25(OH)D-1 α -hydroxylase from the sarcoid macrophages

Sarcoid Clinic,
Niguarda Hospital,
Milan, Italy
G Rizzato

Correspondence to:
Professor G Rizzato, Via
Juvara 9, 20129 Milan, Italy.

differs from the renal enzyme in a number of important respects. In contrast to renal 25(OH)D-24-hydroxylase, 25(OH)D-24-hydroxylase in the alveolar macrophage is stimulated only at very high concentrations of 1,25(OH)₂D₃.³⁵ Unlike mammalian renal cells,³⁷⁻⁴¹ little inhibition of 25(OH)D-1 α -hydroxylase activity occurs in response to 1,25(OH)₂D₃ in pulmonary alveolar macrophages.³⁵ Synthesis of the metabolite is markedly diminished by the addition of dexamethasone directly to the *in vitro* system, and inhibition is dose dependent.^{34, 35} These *in vitro* studies help to account for the clinical observations that serum 1,25(OH)₂D₃ in patients with sarcoidosis is not well regulated and is reduced by glucocorticoids.^{17, 19, 42}

Receptors for 1,25(OH)₂D₃ are present in activated peripheral T lymphocytes from normal human subjects.⁴³ 1,25(OH)₂D₃ was shown to inhibit the proliferation of T cells and to suppress interleukin-2 activity⁴⁴ and γ -interferon synthesis⁴⁵ by phytohaemagglutinin stimulated human peripheral lymphocytes. 1,25(OH)₂D₃ was found to inhibit activated T helper lymphocyte activity from normal human subjects *in vitro*.⁴⁶ If receptors for 1,25(OH)₂D₃ are present in activated pulmonary lymphocytes and if 1,25(OH)₂D₃ inhibits the production of γ -interferon and the proliferation of activated T cells in granulomas of patients with sarcoidosis, production of 1,25(OH)₂D₃ by alveolar macrophages could provide a compensatory mechanism mounted by the immune system to inhibit the inflammatory process.^{47, 48} In other words, 1,25(OH)₂D₃ may be an important downregulator of the intensity of the T lymphocyte activity at sites of disease activity by its ability to limit T helper cell proliferation and to inhibit lymphokine production from these cells.

Pathogenesis of abnormal calcium metabolism

Regardless of the potential role of 1,25(OH)₂D₃ in the modulation of inflammation, it is evident that granulomas provide a non-renal source of 1,25(OH)₂D₃. This has been demonstrated in diseased lymph nodes⁴⁹ and in alveolar macrophages.⁵⁰ This hyperproduction may result in enhanced intestinal absorption of calcium, as shown by balance studies and measurement of calcium absorption with radiolabelled calcium.⁵¹⁻⁵⁴ Consequently hypercalcaemia, hypercalciuria, nephrocalcinosis and renal stones may occur, while serum immunoreactive parathyroid hormone is either suppressed or in the low to normal range.¹⁷⁻¹⁹ Hypercalcaemia usually develops only when the calcium burden coming from the increased intestinal absorption is very high, or when there is some degree of renal insufficiency.¹⁸ Hypercalcaemia varies directly with calcium intake^{52, 53} and can be prevented or corrected by dietary restriction of calcium. Exposure to sunlight or to ultraviolet light may be deleterious because of the induction of skin overproduction of vitamin D₃.⁴⁷ For the same reason a seasonal incidence of hypercalcaemia

may be seen in summer in patients with sarcoidosis.²³

The story, however, is not so simple because increases in urinary hydroxyproline levels, an index of bone resorption, occur in sarcoidosis⁵⁵ which means that some of the excess urinary calcium may originate from the skeleton. In addition, high levels of 1,25(OH)₂D₃ may stimulate osteoclastic activity and bone resorption.⁵⁰⁻⁵⁸

Clinical impact

Hypercalcaemia and hypercalciuria are usually asymptomatic but the toxic effects of calcium on renal tubules may produce symptoms of polyuria, volume depletion, and polydipsia.^{26, 59} Nephrogenic diabetes insipidus and other tubular defects (wasting of potassium, magnesium, phosphate, glucose and amino acids, metabolic acidosis or alkalosis) are described,⁵⁹ but their occurrence is very rare. Depending on its duration and severity, hypercalcaemia may lead, rarely, to acute renal failure, or more frequently to chronic changes in interstitial calcium deposition, and interstitial fibrosis with possible chronic renal insufficiency. Acute hypercalcaemia may result in renal tubule necrosis from intracellular calcium overload and tubule obstruction by calcium precipitates. Nephrocalcinosis occurs in fewer than 5% of patients with sarcoidosis but in more than 50% of patients with renal insufficiency,²⁶ and is the major cause of chronic renal failure in sarcoidosis.⁵⁹ It is found more often in renal biopsy samples or at necropsy than in radiographs. Renal calculi have already been described in this report (see above). Nephrolithiasis may in turn impair renal function by obstructing the urinary tract with resulting hydronephrosis and need for invasive procedures such as lithotripsy, endoscopic treatment, percutaneous intervention or surgical removal.

Radiological evaluation of the skeleton is not included in the work up of the disease as presented in the ATS/ERS/WASOG guidelines at the last Congress of the World Association for Sarcoidosis and Other Granulomatous Disorders held in Essen, Germany in September 1997. Nevertheless, it may show that the small bones of the hands and feet are affected frequently, especially the middle and distal phalanges.⁶⁰ Scattered osteosclerotic changes may also be noted in the skull, long bones, ribs or elsewhere, and may be an occasional finding of a total body scan with gallium-67 (fig 1). Cyst-like lesions of various sizes may also be present occasionally. However, skeletal involvement may be assessed best by bone scintigraphy.⁶¹

Treatment

Hypercalcaemia, hypercalciuria and calcaemic nephropathy may be prevented by a low calcium diet, adequate hydration, and minimisation of exposure to light. Milk, cheese, calcium-containing antacids, and vitamin D should be avoided. Corticosteroids are the mainstay of treatment for more severe hypercalcaemia occurring despite these preventive




Figure 1 Total body scan with gallium-67 showing uptake due to an asymptomatic (and unsuspected) sarcoid bone lesion of the skull.

measures. They block extrarenal synthesis of calcitriol by directly inhibiting macrophage 1α -hydroxylase activity and by suppressing the immune activation of macrophages. In relatively low doses (10–20 mg/day) prednisone is rapidly effective in correcting hypercalcaemia; renal function will be corrected to the extent permitted by any irreversible renal damage that has occurred.

The time honoured advice to eat a diet low in calcium has been extended to most non-sarcoidosis patients with kidney stones. Curhan *et al*⁷² have recently reported the results of a prospective epidemiological study of patients with kidney stones from any cause. The incidence of new kidney stones during a four year follow up was lower by almost 50% in men with the highest calcium intake. The authors suggest reasonably, but without direct supporting data, that this unexpected observation may reflect the effect of increased dietary intake of calcium in precipitating oxalate in the gut, thereby reducing intestinal absorption and urinary excretion of oxalate. How this finding may be applied to sarcoidosis is unknown. In our experience most of the renal stones in patients with sarcoidosis are of calcium oxalate. We advise patients to drink sufficient water to keep the urine volume above two litres per day, and, when oxaluria is above 40 mg/24 hours, to limit their intake of oxalate-rich foods (nuts, pepper, chocolate, dark green vegetables, tomato and fruit).⁶³

Long term corticosteroid therapy may be needed in sarcoidosis for many different reasons. In such cases osteopenia is very frequent and occurs in up to 70% of patients when CT scanning is used.¹⁴ In sarcoidosis the preventive therapy with calcium or vitamin D may be contraindicated so that the options are not so many; however, osteopenia may be reduced in different ways. In a prospective study on chronic patients needing long term corticosteroid therapy we have shown that bone loss and fractures were lower when using deflazacort compared with prednisone,⁶⁴ but the study was not double blind and other studies are needed to confirm such a result. In

another study we have shown that salmon calcitonin may be a good tool for preventing corticosteroid induced osteoporosis in patients with sarcoidosis.⁶⁵ Our results with calcitonin were confirmed in a group of 103 patients (four with sarcoidosis) needing long term corticosteroid therapy.⁶⁶ Bisphosphonates are also good antiresorptive agents and thus are useful for preventing⁶⁷ or treating⁶⁸ corticosteroid-induced osteoporosis. Only one study is underway on the use of alendronate in patients with sarcoidosis and the preliminary results, which are good, were presented at the recent WASOG Congress held in Essen in September 1997.⁶⁹ Oral calcium may be given to patients without hypercalciuria, but calciuria needs careful monitoring in this case. It is clear that we do not have to accept bone loss and high fracture rates as inevitable consequences of high dose glucocorticoid therapy. The challenge now is to make the assessment of the risk of osteoporosis an integral part of the decision to commence glucocorticoid therapy so that treatment may be introduced before fractures occur. Such a practice will avert substantial iatrogenic morbidity in this already disabled group of patients.⁷⁰

For the rare patient who cannot be given corticosteroids there are two other therapeutic options for hypercalcaemia: chloroquine and ketoconazole. Both are inhibitors of 1α -hydroxylase. Chloroquine and hydroxychloroquine^{71 72} have potential retinal toxicity which may limit their use, but this is not the case if the dosage is limited to 250 mg/day. At higher doses a close ophthalmological follow up is suggested in the long term. Ketoconazole has been given in a dose of 800 mg/day for two years to a 47 year old patient with hypercalcaemia with a good result (but with some decrease in serum testosterone levels and libido).⁷³ Two other reports are less favourable because, using the same dosage, renal function deteriorated in two patients after four to six days of treatment⁷⁴ and in one patient the drug had to be discontinued after four months because of hepatotoxic side effects.⁷⁵ Oral phosphates are another therapeutic option because they limit intestinal calcium absorption.⁷⁶

Diuretics may increase or decrease the calcium concentration in plasma and urine depending on the type of diuretic employed.⁷⁷ Thiazide diuretics (hydrochlorothiazide, chlortalidone) decrease the renal excretion of Ca^{++} as a result of a direct action on the early distal tubule, thereby increasing calcaemia. They are contraindicated if the patient has hypercalcaemia, but may be an option to decrease hypercalciuria in normocalcaemic patients if the serum calcium levels are carefully monitored.

Whether or not hypercalciuria unaccompanied by hypercalcaemia or renal stones requires treatment is, however, an open question. Lebacqz *et al*⁷⁸ have suggested administration of 5 g cellulose phosphate daily by mouth, or hydrochlorothiazide in a dose of 100 mg daily. Amiloride also decreases excretion of Ca^{++} .⁷⁷ Our practice in the Milan Sarcoid Clinic is to give to such patients a calciuria decreasing diuretic when two consecutive determinations of

24 hour calciuria are over 500 mg in spite of a low calcium diet. However, in spite of the rational basis, this practice remains poorly investigated and prospective studies are needed.

In contrast, loop diuretics (furosemide) enhance the excretion of Ca^{++} . The calciuric action of these agents is the basis for their use in symptomatic hypercalcaemia. Spironolactone also increases Ca^{++} excretion through a direct effect on tubular transport.

- 1 Besnier E. Lupus pernio de la face. *Am Dermatol Syph (Paris)* 1892;10:333.
- 2 Kreibich K. Uber lupus pernio. *Arch Dermatol Syph (Wien)* 1904; 71: 3-16.
- 3 Bloch B. Beitrag zur kenntnis des pupus pernio. *Monatsschr Prakt Derm* 1907;45:177-84.
- 4 Rieder H. Uber combination von chronischer osteomyelitis (spina ventosa) mit lupus pernio. *Fortschr Roentgenstr* 1910;15:125-35.
- 5 Shaumann J. Etudes histologiques et bacteriologique sur les manifestations medullaires du lymphogranulome benin. *Ann Dermatol Syph (Paris)* 1919;7:385-98.
- 6 Jungling O. Ostitis tuberculosa multiplex cystica (eine eigenartige form der knochentuberkulose). *Fortschr Geb Roentgenstr* 1920;27:375-83.
- 7 Fleischnr F. Die erkrankung der knochen bei lupus pernio und Boeck's miliarlupoid. *Fortschr Geb Rontgenstr* 1924;32: 193-218.
- 8 Jungling O. Uber ostitis tuberculosa multiplex cystoides, zugleich ein beitrag zur lehre von der tuberkuliden des knochens. *Beitr Klin Chir* 1928;143:401-75.
- 9 James DG. Dermatological aspects of sarcoidosis. *Q J Med* 1959;28:109-24.
- 10 Neville E, Carstairs L, James DG. Sarcoidosis of bone. *Q J Med* 1977;46:215-27.
- 11 Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis. *Sarcoidosis* 1991;8:29-34.
- 12 Ste Marie L, Gagné M, Gascon-Barré M, et al. Increased bone resorption and decreased bone formation in osteoporosis due to skeletal sarcoidosis. *Bone and Mineral* 1992;17(Suppl 1):161 (abstract).
- 13 Rottoli P, Gonnelli S, Solitro S, et al. Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. *Sarcoidosis* 1993;10:161-2.
- 14 Rizzato G, Tosi G, Mella C, et al. Prednisone induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. *Sarcoidosis* 1988;5:93-6.
- 15 Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. *Eur Respir J* 1993;6:116-9.
- 16 Harrel G, Fisher S. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium and phosphatase values. *J Clin Invest* 1939;18:687-93.
- 17 Papapoulos S, Clemens T, Fraher L, et al. 1,25-Dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. *Lancet* 1979;ii:627-30.
- 18 Bell N, Stern P, Pantzer E, et al. Evidence that increased circulating 1,25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. *J Clin Invest* 1979;64:218-55.
- 19 Barbour G, Coburn J, Slatopolsky E, et al. Hypercalcaemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. *N Engl J Med* 1981;305:440-3.
- 20 Adams JS, Sharma OP, Gacad MA, et al. Metabolism of 25-hydroxyvitamin D₃ by cultured pulmonary alveolar macrophages in sarcoidosis. *J Clin Invest* 1983;72:1856-60.
- 21 Sharma OP. *Sarcoidosis: a clinical approach*. Springfield, Illinois: Charles C Thomas, 1975: 103.
- 22 Rizzato G, Montemurro L, Fraioli P. Bone mineral content in sarcoidosis. *Semin Respir Med* 1992;13:411-23.
- 23 Taylor R, Lynch H, Wysor WG. Seasonal influence of sunlight on the hypercalcaemia of sarcoidosis. *Am J Med* 1963; 34:221-7.
- 24 James DG, Jones Williams W. Calcium levels. In: James DG, Jones Williams W, eds. *Sarcoidosis and other granulomatous disorders*. Philadelphia: Saunders, 1905: 163-6.
- 25 Lebacqz E, Desmet G, Verhaegen H. Renal involvement in sarcoidosis. *Postgrad Med J* 1970;46:526-9.
- 26 Muther R, McCarron D, Bennet W. Renal manifestations of sarcoidosis. *Arch Intern Med* 1981;141:643-5.
- 27 Kenouch S, Mary JP. Sarcoidosis. In: Cameron S, Davison AM, Grunfeld JP, et al (eds). *Oxford textbook of clinical nephrology*. Oxford: Oxford University Press, 1992: 576-82.
- 28 Rizzato G. Sarcoidosis in Italy. *Sarcoidosis* 1992;9(Suppl 1):145-7.
- 29 Longcope W, Frieman D. A study of sarcoidosis. *Medicine (Baltimore)* 1952;31:1-132.
- 30 Murphy G, Schirmer H. Nephrocalcinosis, urolithiasis and renal insufficiency in sarcoidosis. *J Urol* 1961;86:702-6.
- 31 Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. *Thorax* 1995;50: 555-9.
- 32 Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. *Sarcoidosis, Vasc Diffuse Lung Dis* 1996;13:167-72.
- 33 Adams JS, Singer FR, Gacad MA, et al. Isolation and structural identification of 1,25-dihydroxyvitamin D₃ produced by cultured alveolar macrophages in sarcoidosis. *J Clin Endocrinol Metab* 1985;60:960-6.
- 34 Adams JS, Gacad MA. Characterization of 1 α -hydroxylation of vitamin D₃ sterols by cultured alveolar macrophages from patients with sarcoidosis. *J Exp Med* 1985;161:755-65.
- 35 Reichel H, Koeffler H, Barbers R, et al. Regulation of 1,25-dihydroxyvitamin D production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. *J Clin Endocrinol Metab* 1987;65:1201-9.
- 36 Robinson B, McLemore T, Crystal R. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. *J Clin Invest* 1985;72:1488-95.
- 37 Fukase MS, Avioli LV, Birge SJ, et al. Abnormal regulation of 25-hydroxyvitamin D₃-1 α -hydroxylase activity by calcium and calcitonin in renal cortex from hypophosphatemic mice. *Endocrinology* 1984;114:1203-7.
- 38 Fukase MS, Birge SJ, Rifas L, et al. Regulation of 25-hydroxyvitamin D₃-1 α -hydroxylase activity in serum-free monolayer cultures of mouse kidney. *Endocrinology* 1982;110:1073-5.
- 39 Turner R, Bottemiller B, Howard G, et al. In vitro metabolism of 25-hydroxyvitamin D₃ by isolated rat kidney cells. *Proc Natl Acad Sci USA* 1980;77:1537-40.
- 40 Warner M. Catalytic activity of partially purified renal 25-hydroxyvitamin D hydroxylases from vitamin D-deficient and vitamin D-replete rats. *J Biol Chem* 1982;257:12995-13000.
- 41 Omdahl J. Modulation of kidney 25-hydroxyvitamin D₃ metabolism by 1 α ,25-dihydroxyvitamin D₃ in thyroparathyroidectomized rats. *Life Sci* 1976;19:1943-8.
- 42 Koide Y, Kugai M, Kimura S, et al. Increased 1,25-dihydroxy-cholecalciferol as a cause of abnormal calcium metabolism in sarcoidosis. *J Clin Endocrinol Metab* 1981;52:494-8.
- 43 Provedini D, Tsoukas C, Defetos L, et al. 1,25-Dihydroxyvitamin D₃ receptors in human leucocytes. *Science* 1983;221:1181-3.
- 44 Tsoukas C, Provedini D, Monalagas S. 1,25-Dihydroxyvitamin D₃: a novel immunoregulatory hormone. *Science* 1984;224:1438-40.
- 45 Reichel H, Koeffler H, Tobler A, et al. 1 α ,25-dihydroxyvitamin D₃ inhibits γ -interferon synthesis by normal human peripheral blood lymphocytes. *Proc Natl Acad Sci USA* 1987;84:3385-9.
- 46 Lemire J, Adams J, Kermani-Arab V, et al. 1,25-Dihydroxyvitamin D₃ suppresses human T helper/inducer lymphocyte activity in vitro. *J Immunol* 1985;134:3032-5.
- 47 De Simone D, Bell N. Hypercalcaemia and abnormal vitamin D metabolism. In: Coe F, Favus M, eds. *Disorders of bone and mineral metabolism*. New York: Raven Press, 1992: 563-70.
- 48 Costabel U. Biochemistry. In: James GD, ed. *Sarcoidosis and other granulomatous disorders*. New York: Marcel Dekker, 1994: 433.
- 49 Mason RS, Frankel T, Chan V, et al. Vitamin D conversion by sarcoid lymph node homogenata. *Ann Intern Med* 1984; 100:59-61.
- 50 Adams JS. Abnormal calcium homeostasis in sarcoidosis. *Endocrinol Metab Clin North Am* 1989;18:765-78.
- 51 Anderson J, Dent C, Harper C, et al. Effect of cortisone on calcium metabolism in sarcoidosis with hypercalcaemia, possible antagonistic actions of cortisone and vitamin D. *Lancet* 1954;iii:720-4.
- 52 Henneman P, Dempsey E, Carrol E, et al. The cause of hypercalcaemia in sarcoid and its treatment with cortisone and sodium phytate. *J Clin Invest* 1956;35:1229-42.
- 53 Bell N, Gill J, Bartter F. On the abnormal calcium metabolism in sarcoidosis: evidence for increased sensitivity to vitamin D. *Am J Med* 1964;36:500-13.
- 54 Bell N, Bartter F. Studies of ⁴⁵Ca metabolism in sarcoidosis: evidence for increased sensitivity of bone to vitamin D. *Acta Endocrinol* 1967;54:173-80.
- 55 Studdy P, Bird R, Neville E, et al. Biochemical findings in sarcoidosis. *J Clin Pathol* 1980;33:528-33.
- 56 Meyrier A, Valeyre D, Bouillon R, et al. Different mechanisms of hypercalcaemia in sarcoidosis. *Ann NY Acad Sci* 1986;465:575-86.
- 57 Zerwekh JE, Pake YC, Kaplan RA, et al. Pathogenic role of 1 α -25 dihydroxyvitamin D in sarcoidosis and absorptive hypercalcaemia: different response to prednisone therapy. *J Clin Endocrinol Metab* 1980;51:381-6.
- 58 Reichel H, Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. *N Engl J Med* 1989;320:980-91.
- 59 Casella F, Allon M. The kidney in sarcoidosis. *J Am Soc Nephrol* 1993;3:1555.
- 60 Abdelwahab JF, Norman A. Osteosclerotic sarcoidosis. *Am J Roentgenol* 1988;150:161-2.
- 61 Rohatgi P. Radioisotope imaging in osseous sarcoidosis. *Am J Roentgenol* 1980;134:189-91.
- 62 Curhan G, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med* 1993;328:833-8.
- 63 Lemann J. Composition of the diet and calcium kidney stones. *N Engl J Med* 1993;328:880-2.
- 64 Rizzato G, Riboldi A, Imbimbo B, et al. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. *Respir Med* 1997;91:449-60.

- 65 Montemurro L, Schiraldi G, Fraioli P, *et al.* Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. *Calcif Tissue Int* 1991;**49**:71–6.
- 66 Sambrook P, Birmingham J, Kelly P, *et al.* Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. *N Engl J Med* 1993;**328**:1747–52.
- 67 Adachi J, Bensen W, Brown J, *et al.* Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med* 1997;**337**:382–7.
- 68 Struys A, Snelder A, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. *Am J Med* 1995;**99**:235–42.
- 69 Rottoli P, Gonnelli S, Cappiello V, *et al.* Calcitriol, calcium metabolism and preventive therapy for steroid-induced osteoporosis in sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 1997;**14**(Suppl 1):12 (abstract).
- 70 Reid I. Preventing glucocorticoid-induced osteoporosis. *N Engl J Med* 1997;**337**:420–1.
- 71 O'Leary TJ, Jones G, Lohnes D, *et al.* The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. *N Engl J Med* 1986;**315**:727–30.
- 72 Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis associated with short course chloroquine therapy. *Ann Intern Med* 1989;**111**:437.
- 73 Bia M, Insogna K. Treatment of sarcoidosis-associated hypercalcemia with ketoconazole. *Am J Kidney Dis* 1991;**18**:702.
- 74 Glass AR, Cerletty JM, Elliott W, *et al.* Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in hypercalcemic sarcoidosis. *J Endocrinol Invest* 1990;**13**:407–13.
- 75 Ejaz AA, Zabaneh RI, Tiwari P, *et al.* Ketoconazole in the treatment of recurrent nephrolithiasis associated with sarcoidosis. *Nephrol Dial Transplant* 1994;**9**:1492–4.
- 76 Waron M, Weissgarten J, Gil I, *et al.* Sarcoid nephrocalcinotic renal failure reversed by cellulose phosphate. *Am J Nephrol* 1986;**6**:220–3.
- 77 Weiner I. Diuretics and other agents employed in the mobilization of edema fluid. In: Goodman Gilman A, Rall TW, Nies A, Taylor P, eds. *The pharmacological basis of therapeutics*. New York: Pergamon Press, 1990: 713.
- 78 Lebacqz E, Henrion J, Mayeur S, *et al.* Hypercalciuria in sarcoidosis patients with normocalcemia: pathogenesis and treatment. In: Jones Williams W, Davies B, eds. *Sarcoidosis and other granulomatous diseases*. Cardiff: Alpha Omega, 1980: 215.